LIR Life Sciences Income Statement

Financials in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	FY 2026	FY 2025	FY 2024
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024
Cost of Revenue	0.02	-	-
Gross Profit	-0.02	-	-
Selling, General & Admin	1.76	0.42	0.08
Research & Development	0.06	-	-
Operating Expenses	3.41	0.42	0.08
Operating Income	-3.43	-0.42	-0.08
Currency Exchange Gain (Loss)	-0	-	-
Other Non Operating Income (Expenses)	-0.41	-	-
EBT Excluding Unusual Items	-3.85	-0.42	-0.08
Asset Writedown	-0.1	-	-
Other Unusual Items	0.05	-	-
Pretax Income	-3.9	-0.42	-0.08
Net Income	-3.9	-0.42	-0.08
Net Income to Common	-3.9	-0.42	-0.08
Net Income Growth	-	-	-
Shares Outstanding (Basic)	24	5	0
Shares Outstanding (Diluted)	24	5	0
Shares Change	331.53%	41648.94%	-
EPS (Basic)	-0.17	-0.08	-6.33
EPS (Diluted)	-0.17	-0.08	-6.33
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024
EBITDA	-3.43	-	-
D&A For EBITDA	0	-	-
EBIT	-3.43	-0.42	-0.08
Advertising Expenses	0.81	0.05	-